As an unsecured creditor, a global consumer products company disputed the IP valuation listed in the debtor’s Plan of Reorganization. CRA was hired to assess the valuation of a patent portfolio of the debtor’s manufacturing company in Chapter 11. Through a combination of market research, document review, and financial analysis, CRA was able to identify key elements which were not considered in valuing the patent portfolio. CRA provided expert testimony in US Bankruptcy Court regarding these patent valuation deficiencies. Ultimately, our client received a favorable ruling from the US Bankruptcy Court that resulted in a significant settlement with the debtor.
Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...